Long-Term Potentiation Impairment in Neurodegeneration

Long-Term Potentiation Impairment in Neurodegeneration

Introduction

Long Term Potentiation Impairment In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

[Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) is a persistent strengthening of synapses based on recent patterns of activity. It is considered one of the major cellular mechanisms underlying learning and memory. [LTP](/mechanisms/long-term-potentiation) impairment is a key feature of Alzheimer's Disease and other neurodegenerative conditions. This pathway covers the molecular mechanisms of LTP, how it becomes disrupted in neurodegeneration, and therapeutic approaches. [@malenka2024]

Overview

[Long-term potentiation](/mechanisms/long-term-potentiation) was first described by Bliss and Lømo in 1973 as a lasting increase in synaptic strength following high-frequency stimulation of hippocampal synapses. LTP is widely regarded as the physiological basis for memory formation and is critically dependent on [NMDA receptor](/entities/nmda-receptor) function, calcium signaling, and synaptic protein synthesis. [@lynch2024]

Molecular Mechanisms of LTP

```mermaid
flowchart TD
A["High-Frequency Stimulation"] --> B["Glutamate Release"]

B --> C["NMDA Receptor Activation"]
B --> D["AMPA Receptor Activation"]

C --> E["Mg2+ Block Relief"]
E --> F["Ca2+ Influx"]

D --> G["Depolarization"]
G --> E

Long-Term Potentiation Impairment in Neurodegeneration

Introduction

Long Term Potentiation Impairment In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

[Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) is a persistent strengthening of synapses based on recent patterns of activity. It is considered one of the major cellular mechanisms underlying learning and memory. [LTP](/mechanisms/long-term-potentiation) impairment is a key feature of Alzheimer's Disease and other neurodegenerative conditions. This pathway covers the molecular mechanisms of LTP, how it becomes disrupted in neurodegeneration, and therapeutic approaches. [@malenka2024]

Overview

[Long-term potentiation](/mechanisms/long-term-potentiation) was first described by Bliss and Lømo in 1973 as a lasting increase in synaptic strength following high-frequency stimulation of hippocampal synapses. LTP is widely regarded as the physiological basis for memory formation and is critically dependent on [NMDA receptor](/entities/nmda-receptor) function, calcium signaling, and synaptic protein synthesis. [@lynch2024]

Molecular Mechanisms of LTP

Key Phases

| Phase | Duration | Key Mechanisms | [@selkoe2022]
|-------|----------|----------------| [@hsieh2023]
| Induction | Seconds | NMDA receptor activation, Ca²⁺ influx, CaMKII activation | [@lisman2022]
| Expression | Hours | AMPA receptor phosphorylation, insertion, trafficking | [@kamenetz2023]
| Maintenance | Days-Weeks | New protein synthesis, structural changes | [@ittner2024]

Critical Molecules

| Molecule | Role in LTP | [@lambert2023]
|----------|--------------| [@kandel2024]
| NMDA receptor (GluN2A/B) | Calcium entry, coincidence detection |
| AMPA receptor (GluA1/2) | Synaptic transmission, trafficking |
| CaMKIIα | Autophosphorylation, LTP maintenance |
| Ras-ERK pathway | Protein synthesis, gene transcription |
| mTORC1 | Local protein synthesis |
| PSD-95 | Scaffolding, receptor anchoring |

LTP in Alzheimer's Disease

Amyloid-Beta Effects

Synaptic Receptor Dysfunction

• [Aβ](/proteins/amyloid-beta) oligomers bind to NMDA receptors
• Enhanced NMDA receptor internalization
• Reduced synaptic AMPA receptor expression
• Impaired receptor trafficking

Calcium Dysregulation

• Aβ forms calcium-permeable channels
• Mitochondrial calcium overload
• Calcineurin overactivation
• Disruption of calcium-dependent LTP mechanisms

Synaptic Plasticity Impairment

• Inhibits LTP induction
• Shifts LTP threshold
• Reduces synaptic strength
• Affects both CA1 and dentate gyrus

Tau Pathology Effects

Direct Synaptic Dysfunction

• [Tau](/proteins/tau) mislocalization to [dendritic spines](/cell-types/dendritic-spines)
• Impairs NMDA receptor trafficking
• Disrupts AMPA receptor cycling
• Affects spine morphology

Loss of Tau Function

• Tau is essential for LTP in vivo
• Tau knockdown impairs LTP
• MT dynamics disruption affects trafficking

APOE4 Effects

• APOE4 carriers show reduced LTP
• Impaired synaptic plasticity
• Enhanced Aβ toxicity
• Altered synaptic signaling

LTP in Parkinson's Disease

Dopaminergic Modulation

• D1/D5 receptors enhance LTP in striatum
• Dopamine loss impairs corticostriatal LTP
• Deficits in reward-related learning

Synaptic Dysfunction

• [Alpha-synuclein](/proteins/alpha-synuclein) affects synaptic proteins
• Impaired vesicle release
• Reduced neurotransmitter availability

L-DOPA Effects

• Chronic L-DOPA can impair LTP
• Dyskinesia associated with plasticity changes

LTP in Other Neurodegenerative Diseases

Huntington's Disease

• Impaired corticostriatal LTP
• Mutant [huntingtin](/proteins/huntingtin) affects synaptic plasticity
• NMDA receptor dysfunction
• Early synaptic deficits

ALS

• Corticomotor neuron LTP impaired
• Synaptic hyperexcitability
• Reduced excitatory synaptic transmission

Frontotemporal Dementia

• Synaptic dysfunction prominent
• Tau and [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology
• Memory circuit disruption

Therapeutic Strategies

Enhancing LTP

| Target | Approach | Stage |
|--------|----------|-------|
| NMDA receptors | Partial agonists, modulators | Preclinical |
| AMPA receptors | Positive allosteric modulators | Phase 2 |
| mTORC1 | Rapamycin, rapamycin analogs | Preclinical |
| cAMP/PKA | PDE inhibitors | Phase 2 |
| BDNF | BDNF mimetics, gene therapy | Preclinical |

Removing LTP Inhibitors

| Target | Approach | Stage |
|--------|----------|-------|
| Aβ | Immunotherapy, secretase inhibitors | Phase 2/3 |
| Tau | Anti-tau antibodies, aggregation inhibitors | Phase 2 |
| Aβ-oligomers | Specific antibodies, small molecules | Preclinical |

Synaptic Repair

| Target | Approach | Stage |
|--------|----------|-------|
| Spine morphology | Spine enhancers | Preclinical |
| Receptor trafficking | Modulators | Preclinical |
| Scaffold proteins | Gene therapy | Preclinical |

LTP as a Biomarker

Electrophysiological Measures

• EPSP slope: Synaptic efficacy
• Population spike: Neuronal firing
• Paired-pulse facilitation: Presynaptic function

Behavioral Correlates

• Morris water maze performance
• Novel object recognition
• Contextual fear conditioning
• Working memory tasks

Cross-Links

• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Glutamate Excitotoxicity](/mechanisms/glutamate-excitotoxicity-pathway)
• [Calcium Dysregulation](/mechanisms/calcium-dysregulation-alzheimers)
• [Memory Circuitry](/mechanisms/memory-circuits-hippocampus)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease-disease)

Background

The study of Long Term Potentiation Impairment In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 31%

Recent Research Updates (2024-2026)

• [Li S et al., Neural Regen Res (2025 Mar 25)](https://pubmed.ncbi.nlm.nih.gov/40145988/)
• [Jiang R et al., Mol Neurobiol (2024 Sep)](https://pubmed.ncbi.nlm.nih.gov/38374316/)

References